An interventional study of dehydroepiandrosterone in Infertility, sponsored by ShangHai Ji Ai Genetics & IVF Institute. Terminated at 1 site in China. Open to female participants aged 22 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-06-24.
Sponsored by ShangHai Ji Ai Genetics & IVF Institute · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing dehydroepiandrosterone in Infertility — 2 open to participants now, 2 under way, 1 of them phase 3. Dehydroepiandrosterone · Infertility.
Among the 13 studies testing dehydroepiandrosterone in Infertility, this one is the 9th largest by enrollment, is one of 3 that started in 2014, is one of 3 with no phase, and was the 6th registered.
2,090 studies on the registry are indexed under Infertility; 355 are open to participants now.
Browse Infertility studies →2 of the 13 studies testing dehydroepiandrosterone in Infertility are open now, in 2 countries. Recruiting first, the newest first:
Beni-Suef University · Sites in Egypt
Ages 18–35 · Women only
The Affiliated Hospital of Inner Mongolia Medical University · Sites in China
Ages 21–42 · Women only
By country, each count listing its studies:
Dehydroepiandrosterone: first FDA approval 2016 (INTRAROSA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 232 Infertility studies recruiting now, 43 (19%) set no upper age limit and 183 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.
This study: 22 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 7 · Phase 4 2
First in 2007; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is below the median of 133 across 1,415 interventional studies indexed under Infertility.
Median enrollment 140 across the 13 interventional studies. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 13 has an industry lead sponsor. The 9 most frequent:
ShangHai Ji Ai Genetics & IVF Institute is the lead sponsor of 26 studies on the registry; 5 are open to participants now.
ShangHai Ji Ai Genetics & IVF Institute has 4 studies filed under Infertility — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing dehydroepiandrosterone in Infertility, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The supplementation of Dehydroepiandrosterone (DHEA) has been used in some centers for patients with previous poor ovarian reserve and response in an attempt to improve pregnancy outcomes. However, there still has controversy on the clinical effect on the 75mg/d for the use,especially in Asian people. Whether the double dosage of DHEA in patients with poor ovarian reserve and response in China can improve the IVF outcome with little side effect is unknown.
The aim of this randomized controlled study is to compare the effect of a higher dose (150mg daily) and a standard dose (75mg daily) of DHEA on the number of oocytes obtained in poor ovarian responders. The effect of DHEA action on the cumulus cells will be examined.
Consecutive infertile women attending the subfertility clinic at Shang Hai Ji Ai Genetics \&IVF Institute for IVF treatment will be approached. Those fulfilling the selection criteria stated below would be recruited and a written consent will be obtained after detailed explanation and counseling.
Poor ovarian responders are defined according to the Bologna criteria fulfilling 2 out of 3 of the following:
(i) Advanced maternal age (>/= 40) or any other genetic or acquired risk factor for poor ovarian response(POR); (ii) Previous poor ovarian response (POR) (\</= 3 oocytes with a conventional stimulation protocol using at least 150 international units (IU) gonadotrophins per day) (iii) Abnormal ovarian reserve test [i.e. antral follicle count (AFC) \< 5-7 or antimüllerian hormone (AMH) \< 0.5 - 1.1ng/ml]
Alternatively, two episodes of POR after maximal stimulation are sufficient to define a patient as poor responder in the absence of advanced maternal age or abnormal ovarian reserve test(ORT).
Baseline assessment will be performed at early follicular phase (Day 2 or 3) at recruitment. Patient characteristics including age, Body Mass Index (BMI), and smoking status would be recorded and blood test including follicular stimulating hormone (FSH), estradiol (E2), testosterone, DHEA-S, full blood count, renal and liver function test would be checked. Pelvic scan will be performed to assess the total AFC and total ovarian volume.
Subjects will be randomized divided into two groups:
Hormonal profile, ultrasound assessment, full blood count, renal and liver function test will be repeated in follicular phase (D2 or 3) of every month or cycle followed by a IVF treatment using antagonist protocol based on our standard departmental regimen. The human menopausal gonadotropin (hMG) injections were started at 300 international units (IU) for 2 days followed by 300 international units (IU) daily. Improvement of ovarian reserve markers would be assessed by the change in serum AMH between the time of recruitment and that after 6 and 12 weeks of DHEA. Cycle characteristics including the dose of gonadotrophins use, duration of stimulation, number of oocytes obtained, number of fertilized embryos and good quality embryos will be recorded and follicular fluid will be saved for hormonal profiles.
Statistics
Statistical tests
Statistical comparisons will be performed according to the intention to treat principle by Student t test or Fisher's exact tests for normally distributed data and Mann-Whitney test for skewed data. Chi-square test would be used for binary variables. Statistical analyses will be performed using the Statistical Package for (the) Social Sciences (SPSS) software and a P-value of 0.05 would be considered statistically significant. Linear regression analysis / logistic regression analysis curve would be used to evaluate the age, BMI, smoking, FSH, E2, AMH, testosterone, DHEA-S, AFC, ovarian volume and duration of DHEA use for the prediction of improved ovarian reserve after DHEA supplementation.
The number of oocytes retrieved will be used as the primary outcome of the study. Based on our own database for patients undergoing IVF treatment, the mean oocytes obtained was 2.7 with a standard deviation (SD) of 1.4. Assuming an increase of oocytes obtained by 1.0 to be clinically significant, 18 subjects in each arm would be required to achieve a test of significance of 0.05 and a power of 0.8. Considering possible dropouts, we aim at recruiting 18 patients in each arm, i.e. 36 patients.
In order to compare one of the secondary outcome -- AMH (which has more relevance on the effect of ovarian response) with adequate power, based on our own database for patients undergoing IVF treatment, the mean AMH of the group with poor ovarian reserve is 0.8 with a SD of 0.6. Assuming an increase of number of oocyte retrieved by 0.5 to be clinically significant, 25 subjects in each arm would be required to achieve a test of significance of 0.01 and a power of 0.9. Totally 50 patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients were excluded if they:
dehydroepiandrosterone,DHEA,capsule, 50mg/capsule, one capsule t.i.d..
Dietary Supplement: dehydroepiandrosterone
dehydroepiandrosterone,DHEA, capsule, 25mg/capsule, one capsule t.i.d.
Dietary Supplement: dehydroepiandrosterone
high dose group treatment represent for 50mg t.i.d. Patients in these group will take one capsule each time and three times a day for three months before entering into IVF cycles.
Also known as: DHEA (Lab Hercules™)
The Number of Oocytes Obtained
After 12 weeks treatment, the number of oocytes obtained will be detected from the higher dose group and standard dose group
Time frame: After taking DHEA for 12 weeks
AFC
Antral follicle count (AFC)
Time frame: After taking DHEA for 12 weeks
Follicle Stimulating Hormone (FSH) Levels
The change of FSH levels in the three groups.
Time frame: 12 weeks after taking DHEA
E2
Serum E2 levels
Time frame: 12 weeks after taking DHEA
The Number of Follicles>10mm
The number of follicles\>10mm represent for the ovarian reserve and response
Time frame: 12 weeks after taking DHEA
AMH
The change of AMH levels in serum
Time frame: baseline and 12 weeks
Testosterone
Time frame: 12 weeks after taking DHEA
Dehydroepiandrosterone-Sulfide (DHEA-S)
Time frame: 12 weeks after taking DHEA
Insulin-like Growth Factor-1 (IGF-1)
Time frame: 12 weeks after taking DHEA
The Number of Mature Oocytes Obtained
Time frame: up to 12 weeks
Pregnancy Rate
The rate of clinical pregnancy
Time frame: 2 weeks after transfer
the Numbers of Fertilized Embryos
Time frame: 12 weeks after taking DHEA
the Numbers of Cleaved Embryos
Time frame: After taking DHEA for 12 weeks
the Numbers of Top-quality Embryos.
top-quality embryos are represented for \>7cell on Day 3 and the fragments \<20%
Time frame: 12 weeks after taking DHEA
| Milestone | Standard Dose Group | High Dose Group |
|---|---|---|
| Started | 30 | 30 |
| Completed | 30 | 30 |
| Not completed | 0 | 0 |
After 12 weeks treatment, the number of oocytes obtained will be detected from the higher dose group and standard dose group
| oocytes | High Dose Group | Standard Dose Group |
|---|---|---|
| The Number of Oocytes Obtained | 3.82 ± 0.28 | 2.51 ± 0.22 |
Antral follicle count (AFC)
| follicles | High Dose Group | Standard Dose Group |
|---|---|---|
| AFC | 4.00 ± 0.20 | 4.66 ± 0.26 |
The change of FSH levels in the three groups.
| IU/L | High Dose Group | Standard Dose Group |
|---|---|---|
| Follicle Stimulating Hormone (FSH) Levels | 12.84 ± 0.99 | 11.69 ± 0.83 |
Serum E2 levels
| pmol/L | High Dose Group | Standard Dose Group |
|---|---|---|
| E2 | 51.88 ± 5.64 | 39.11 ± 4.44 |
The number of follicles\>10mm represent for the ovarian reserve and response
| follicles | High Dose Group | Standard Dose Group |
|---|---|---|
| The Number of Follicles>10mm | 8.24 ± 0.32 | 3.71 ± 0.24 |
The change of AMH levels in serum
| ng/ml | High Dose Group | Standard Dose Group |
|---|---|---|
| AMH | 3.05 ± 0.42 | 1.62 ± 0.15 |
| ng/dl | High Dose Group | Standard Dose Group |
|---|---|---|
| Testosterone | 31.67 ± 2.6 | 31.59 ± 1.94 |
| ug/ml | High Dose Group | Standard Dose Group |
|---|---|---|
| Dehydroepiandrosterone-Sulfide (DHEA-S) | 2.69 ± 0.24 | 1.75 ± 0.20 |
| ng/ml | High Dose Group | Standard Dose Group |
|---|---|---|
| Insulin-like Growth Factor-1 (IGF-1) | 90.87 ± 6.50 | 71.85 ± 4.39 |
| oocytes | High Dose Group | Standard Dose Group |
|---|---|---|
| The Number of Mature Oocytes Obtained | 4.1 ± 0.24 | 1.93 ± 0.27 |
The rate of clinical pregnancy
| percentage of pregnancy | High Dose Group | Standard Dose Group |
|---|---|---|
| Pregnancy Rate | 7 | 4 |
| embryos | High Dose Group | Standard Dose Group |
|---|---|---|
| the Numbers of Fertilized Embryos | 1.70 ± 0.17 | 1.92 ± 0.21 |
| embryos | High Dose Group | Standard Dose Group |
|---|---|---|
| the Numbers of Cleaved Embryos | 1.63 ± 0.19 | 1.89 ± 0.23 |
top-quality embryos are represented for \>7cell on Day 3 and the fragments \<20%
| embryos | High Dose Group | Standard Dose Group |
|---|---|---|
| the Numbers of Top-quality Embryos. | 1.11 ± 0.15 | 0.85 ± 0.13 |
Collected over 3 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| High Dose Group | — | 0/30 (0%) | 0/30 (0%) |
| Standard Dose Group | — | 0/30 (0%) | 0/30 (0%) |
| Age, Categorical(Participants) | High Dose Group | Standard Dose Group | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 30 | 30 | 60 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | High Dose Group | Standard Dose Group | Total |
|---|---|---|---|
| Mean | 38.40 ± 4.70 | 37.68 ± 5.40 | 38.3 ± 5.05 |
| Sex: Female, Male(Participants) | High Dose Group | Standard Dose Group | Total |
|---|---|---|---|
| Female | 30 | 30 | 60 |
| Male | 0 | 0 | 0 |
Plan to share: No
Ran from Jan 2014 to primary completion in Dec 2014, 11 months.
Results were first posted in Jun 2025, 10 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dehydroepiandrosterone
ShangHai Ji Ai Genetics & IVF Institute